Federal Agency
Appears in 5 stories
Covers tests only after symptoms appear; ASAP Act pending
Alzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.
Updated 3 days ago
Issuing proposed procedural notice; TCET pathway paused for new candidates
For nearly a decade, medical device makers have faced the same bottleneck: the FDA clears a breakthrough device, and then Medicare spends another year or more deciding whether to pay for it. On April 23, 2026, the two agencies jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway — it cuts that timeline to as little as two months. They simultaneously paused the existing Transitional Coverage for Emerging Technologies (TCET) program for new applicants, consolidating all breakthrough-device coverage work under RAPID.
Updated May 31
Source of baseline spending projections and historical data
For decades, American health care spending grew faster than the economy. Government actuaries projected in 2010 that it would hit 21.2 percent of GDP by 2024 (about $6.3 trillion), but actual spending came in at 18%, roughly $977 billion less.
Administering BALANCE model to expand GLP-1 access
Medicare has been banned from covering weight loss drugs since 2003. CMS launched BALANCE in December 2025, a voluntary model offering $50-per-month Ozempic and Wegovy access for 10% of Medicare enrollees starting July 2026.
Updated May 16
Linked to a new CBD access pilot described alongside the executive order
Trump's executive order instructing DOJ to fast-track marijuana's move to Schedule III immediately triggered a familiar split. Public health and industry groups cheered the potential research and tax impacts, while House Republicans organized opposition, urging Trump to keep marijuana in Schedule I.
Updated May 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?